Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: EU Assessing Booster Dose Of Pfizer/BioNTech’s Comirnaty

Inflammatory Syndrome Side-Effect Also Under Investigation

Executive Summary

As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.

You may also be interested in...



EMA 'Confident' Of New COVID-19 Vaccine Approvals By Year End

The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.

COVID-19: EMA Says Guillain-Barré Syndrome Is A Side-Effect Of AZ’s Vaxzevria

The EU’s pharmacovigilance committee has recommended safety updates for two COVID-19 vaccines, and is keeping its eye on a range of possible side-effects with all four authorized products.

Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised

ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel